---
title: "NKGen Biotech, Inc. (NKGN.US) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/NKGN.US/overview.md"
symbol: "NKGN.US"
name: "NKGen Biotech, Inc."
parent: "https://longbridge.com/zh-CN/quote/NKGN.US.md"
datetime: "2026-04-05T10:35:07.106Z"
locales:
  - [en](https://longbridge.com/en/quote/NKGN.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NKGN.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NKGN.US/overview.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/NKGN.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/NKGN.US/overview.md)


# NKGen Biotech, Inc. (NKGN.US) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | Biotechnology |
| 交易所 | US Market |
| 地址 | 3001 Daimler Street, Santa Ana, California, United States |
| 官网 | [nkgenbiotech.com](https://nkgenbiotech.com) |

## 公司简介

NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HER2-CAR NK cell therapy candidate in pre-clinical trial to treat refractory solid tumors. It has a strategic partnership with HekaBio K.K., a Japan-based healthcare platform, to develop, conduct clinical trials, obtain regulatory approvals, manufacture, and commercialize the company’s autologous NK cell therapy product candidates for central nervous system and autoimmune conditions in Japan. The company also has a license agreement with NKMAX Co., Ltd.

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Paul Y. Song | CEO & Chairman |
| James A. Graf | Interim Chief Financial Officer |
| Yoonmi Kang | SVP of Technical Ops & Development |
| Yong Man Kim | Chief Scientific Officer |
| Irene Chang | SVP, HR & Corporate Culture |
| Michael L. Klowden | Independent Director |
| Kathleen D. Scott | Independent Director |
| Anthony T. Reder | Member of Scientific Advisory Board |
| Craig Blackstone | Member of Scientific Advisory Board |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| CFIC-2015 NV Family Investments, LLC | 16.66% | 2025-10-07 |
| Paul Y. Song | 16.10% | 2025-10-07 |
| NKMAX CO., Ltd. | 7.75% | 2025-10-07 |
| HekaBio K.K. | 6.13% | 2025-10-07 |
| Meteora Capital, LLC | 2.11% | 2025-12-31 |
| James A. Graf | 1.60% | 2025-10-07 |
| Peggy Tsiang Cherng | 1.60% | 2024-08-12 |
| Yong Man Kim | 0.02% | 2025-10-07 |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**